Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 3,742,900 shares, a decline of 5.0% from the May 15th total of 3,940,300 shares. Approximately 4.3% of the shares of the company are short sold. Based on an average daily trading volume, of 312,200 shares, the days-to-cover ratio is currently 12.0 days.
Adaptimmune Therapeutics stock traded down $0.17 during trading hours on Friday, reaching $3.27. 183,338 shares of the company’s stock traded hands, compared to its average volume of 160,488. The company has a debt-to-equity ratio of 0.12, a current ratio of 8.55 and a quick ratio of 8.55. Adaptimmune Therapeutics has a fifty-two week low of $3.20 and a fifty-two week high of $14.54. The company has a market cap of $342.34 million, a price-to-earnings ratio of -3.41 and a beta of 1.63. The business’s 50 day moving average price is $3.63.
Adaptimmune Therapeutics (NASDAQ:ADAP) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 45.03%. On average, analysts forecast that Adaptimmune Therapeutics will post -1.17 EPS for the current fiscal year.
Several equities research analysts have recently weighed in on ADAP shares. Leerink Swann lowered shares of Adaptimmune Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.15 target price on the stock. in a report on Tuesday, May 7th. ValuEngine lowered shares of Yext from a “strong-buy” rating to a “buy” rating in a report on Friday, May 10th. BidaskClub lowered shares of Xencor from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 11th. Raymond James decreased their price objective on shares of Adaptimmune Therapeutics from $16.00 to $6.00 and set an “outperform” rating on the stock in a report on Tuesday, May 7th. Finally, Citigroup set a $14.00 price objective on shares of Coty and gave the stock a “hold” rating in a report on Thursday, May 30th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $6.59.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
See Also: What is dollar cost averaging (DCA)?
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.